Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 5/20 | 0.50 |
| ▸ | IDH1 | O75874 | 5/20 | 0.47 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 0.46 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25257529 | 1.00 | KCNT1 (0.63) | KCNT1KMT2AIDO1IDH1KCNQ1 | |
| SCHEMBL25266725 | 0.91 | KCNT1 (0.64) | KCNT1KMT2AKCNQ1KCNH2CACNA1C | |
| SCHEMBL25212563 | 0.91 | KCNT1 (0.64) | KCNT1KMT2AKCNQ1KCNH2CACNA1C | |
| SCHEMBL30102366 | 0.90 | KCNT1 (0.61) | KCNT1KMT2AIDO1IDH1KCNQ1 | |
| SCHEMBL25268263 | 0.90 | KCNT1 (0.61) | KCNT1KMT2AIDO1IDH1KCNQ1 | |
| SCHEMBL25208909 | 0.90 | KCNT1 (0.61) | KCNT1KMT2AIDO1IDH1KCNQ1 | |
| SCHEMBL25215039 | 0.90 | KCNT1 (0.65) | KCNT1KMT2AKCNQ1KCNH2CACNA1C | |
| SCHEMBL25267623 | 0.90 | KCNT1 (0.65) | KCNT1KMT2AKCNQ1KCNH2CACNA1C | |
| SCHEMBL25246585 | 0.90 | KCNT1 (0.67) | KCNT1KMT2AKCNQ1KCNH2CACNA1C | |
| SCHEMBL25246588 | 0.90 | KCNT1 (0.67) | KCNT1KMT2AKCNQ1KCNH2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4692069-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4110317-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| CN-115443129-A | KCNT1 inhibitors and methods of use | 普拉西斯精密医药公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583849-B2 | KCNT1 inhibitors and methods of use | KCNT1, SCN1A, KCNT2 | KCNT1 1/4885KMT2A 832/4885IDO1 3169/4885 |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | KCNT1 1/4885KMT2A 232/4885IDO1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.